TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02797158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVI procedure
Description: Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
Study: NCT01704456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy
Description: The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
Study: NCT01286571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 135585
Description: one oral single dose per subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 135585
Description: one oral single dose per subject
Study: NCT03914677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine Oral Tablet
Description: nicotinic antagonist (ganglionic blocker)
Study: NCT04566146

Intervention type: OTHER
Group type: OTHER
Intervention: scapular muscle training, serratus anterior strength, scapular stabilization exercises
Description: patients will be scheduled to attend physical therapy three sessions per week for one month. Three sets of 10 repetitions for each exercise were prescribed per session, with a 1-minute rest between sets.
Study: NCT02383771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: (Ticagrelor 90mg Bid) x 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin + Ticagrelor
Description: (Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No Anti-platelet Therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin + Ticagrelor
Description: Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
Study: NCT01873248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
Study: NCT02779621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-collecting a vaginal sample with a swab for HPV testing
Description: The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collection of cervical sample for routine cervical screening
Description: This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of cervical sample for routine cervical screening
Description: This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
Study: NCT00877929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80
Description: Telmisartan 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10
Description: Amlodipine 5 for two weeks, then forced titration to Amlodipine 10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10
Description: Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
Study: NCT01486979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol, 10 mcg
Description: One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol, 25 mcg
Description: One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
Study: NCT01822912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart Failure Disease Management Program
Description: Subjects will be assessed 3 times a week while in SNF.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Heart Failure Usual Care
Description: Subjects will receive standard of care.
Study: NCT04678557

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VC-01 Combination Product
Description: PEC-01 cells loaded into an Encaptra Drug Delivery System

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VC-01 Combination Product
Description: PEC-01 cells loaded into an Encaptra Drug Delivery System
Study: NCT01759095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic multidrug blister pack
Description: At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
Study: NCT02934464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Study: NCT01493921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-T100 gel
Description: Patient will be instructed to self-apply approximately 0.3\~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
Study: NCT03447912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Condition
Description: The intervention approach will be informed by the Community Coalition Action Theory (CCAT) developed by Butterfoss and Kegler. CCAT posits that coalitions form due to a threat, opportunity, or mandate. Public health center staff will form a coalition by recruiting partner organizations from civil society and other government sectors (e.g., health care, education), conduct situational assessment, and develop and implement action plans to promote the adoption and enforcement of smoke-free policies in public indoor and and outdoor spaces.
Study: NCT03015688

Intervention type: RADIATION
Intervention: x-ray images

Intervention type: RADIATION
Intervention: x-ray images
Study: NCT01049698

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: 3 d/wk resistance training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training + Diet
Description: 3 d/w resistance training plus 600 kcal/d deficit
Study: NCT02165202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilpivirine
Description: Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
Study: NCT03874949

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEALITE Regular
Description: Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEALITE Ultra
Description: Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).~The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.
Study: NCT04169802

Intervention type: DIAGNOSTIC_TEST
Intervention: Retinal Health Monitoring System Visual Acuity Module
Description: Assessment of corrected near visual acuity

Intervention type: DIAGNOSTIC_TEST
Intervention: Retinal Health Monitoring System Visual Acuity Module
Description: Assessment of corrected near visual acuity
Study: NCT02515955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
Study: NCT04169802

Intervention type: DIAGNOSTIC_TEST
Intervention: Sloan letter, logarithmic near visual acuity chart (Reference Chart)
Description: Assessment of corrected near visual acuity

Intervention type: DIAGNOSTIC_TEST
Intervention: Sloan letter, logarithmic near visual acuity chart (Reference Chart)
Description: Assessment of corrected near visual acuity
Study: NCT02515955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
Study: NCT01601210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate or placebo
Description: Placebo, 2g, 4g, and 10g of creatine monohydrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate or placebo
Description: Placebo, 2g, 4g, and 10g of creatine monohydrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate or placebo
Description: Placebo, 2g, 4g, and 10g of creatine monohydrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Creatine monohydrate or placebo
Description: Placebo, 2g, 4g, and 10g of creatine monohydrate
Study: NCT05987436

Intervention type: OTHER
Intervention: Supervised Aerobic Exercise
Description: Group 1 exercised for six weeks, five sessions per week under the supervision of a medical doctor in the aerobic exercise laboratory.
Study: NCT00975663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus and MMF
Description: Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus and MMF
Description: Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
Study: NCT03664583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACHRU-Community Partnership Program (CPP)
Description: The intervention is a 6-month community navigation and self-management program for patients with diabetes and at least one additional chronic condition, and their caregivers, to improve health outcomes. The intervention will be provided by an interprofessional team of providers and consists of six core components.
Study: NCT01381536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1550188 1mg/kg or 10mg/kg
Description: IV one shot
Study: NCT02264548

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radio-Ablation
Description: Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5
Study: NCT02076906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance High Intensity Focused Ultrasound
Description: MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
Study: NCT01067365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: 12.5 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: 25 mg once daily
Study: NCT03346967

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: adipose-derived mesenchymal stem cells
Description: Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: adipose-derived mesenchymal stem cells
Description: Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure
Study: NCT00909740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEGF0444A
Description: Intravenous escalating dose
Study: NCT03342092

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires distributed to the families 15 days before child's medical consultation + anthropometric measures and data collected from the personal interview with school nurse
Study: NCT00779207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss and exercise
Description: 10% weight loss through diet and exercise plus multicomponent exercise training three times a week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss
Description: 10 percent weight loss through diet and behavioral modification
Study: NCT01781780

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Nutrition Recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast Recommendation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Breakfast Recommendation
Study: NCT00953563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unite Biomatrix
Description: collagen based, decellularized equine pericardial dressing for skin surface wounds
Study: NCT00548899

Intervention type: DRUG
Group type: OTHER
Intervention: Nexavar (Sorafenib)
Description: Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
Study: NCT01124955

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The intervention group (IG) are submitted to five acupuncture sessions using Yamamoto New Scalp Acupuncture(YNSA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-penetrating acupuncture
Description: The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
Study: NCT01633177

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D3 placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D3 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study: NCT02744417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling
Description: Multidisciplinary smoking cessation counseling, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures delivered by physicians, psychologist-assisted cognitive behavioural therapy, and counseling provided by dentists during the active phase of the treatment and maintenance session, using motivational interviewing techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Description: Full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: Nicotine replacement therapy: chewing gum (Nicorette chewing gum 2-4mg) and patches (Nicorette patches 15-25mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride
Description: bupropion hydrochloride 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 0,5mg
Study: NCT01441466

Intervention type: OTHER
Intervention: Isolation
Description: Patients in this arm are nursed together (in the same room) independent of viral agent
Study: NCT01569230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized Acupuncture
Description: The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized Acupuncture
Description: The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Waiting
Description: No interventions were applied to the patients in this group.
Study: NCT03582696

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CHANGE Study
Description: The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
Study: NCT03778463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synovectomy
Description: Removal of the synovium during total knee arthroplasty
Study: NCT04671992

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Out of-Plane Technique and In-Plane on
Description: A comparison of out of-plane technique and in-plane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Out of-Plane Technique and In-Plane on
Description: A comparison of out of-plane technique and in-plane
Study: NCT05323097

Intervention type: OTHER
Intervention: Drowning-related OHCA
Description: Drowning-related out-of-hospital cardiac arrest (OHCA): YES
Study: NCT01515046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine with escalating ascorbic acid
Description: Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)
Study: NCT03100110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCognitive Communicator
Description: Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.